Julie Kim is the President of Plasma-Derived Therapies Business Unit for Takeda, responsible for building a sustainable, high growth business focused on meeting the large and growing demand for plasma-derived products, essential for effectively treating patients with a variety of rare, life-threatening, chronic and genetic diseases across the world.
Prior to Takeda, Julie was the Global Franchise Head for Hematology at Shire, where she had responsibility for providing cross-functional strategic leadership for the business Previously at Shire, she was Head of International Value Demonstration & Access for the entire Shire portfolio outside of the US, which included developing innovative models and developing and executing tender management excellence and public private partnerships.
Earlier at Baxter/Baxalta, Julie held a number of diverse roles with increasing responsibility in various functions, including Head of Business Model Innovation, North/South Europe Cluster Head for Immunology, General Manager for Baxter UK/Ireland and Global Franchise Head for Immunology. In total, she spent 10 years dedicated to the Immunology and plasma business where she worked closely with R&D, manufacturing and BioLife organizations, having initially begun her career in U.S. healthcare consulting.
Julie is known as an inclusive leader who has a track record of delivering enterprise value through strong engagement and patient focus. Her experiences across multiple therapy areas, geographies and functions bring a broad perspective to her leadership style.
She has an MBA from the J. L. Kellogg Graduate School of Management at Northwestern University and a BA in Economics from Dartmouth College. Julie was also a 2013 Healthcare Businesswomen’s Association (HBA) Rising Star.